NEUROEPIDEMIOLOGY
metrics 2024
Exploring the Intersection of Neurology and Public Health.
Introduction
NEUROEPIDEMIOLOGY, published by KARGER, stands as a leading journal in the fields of epidemiology and neurology, with a remarkable impact reflected in its Q1 ranking in both categories for 2023. Since its inception in 1982, the journal has been pivotal in advancing our understanding of neurological disorders through a rigorous scientific lens, making significant contributions to both clinical practice and public health policies. Based in Switzerland, it attracts a global readership of researchers, healthcare professionals, and students committed to leveraging epidemiological insights to combat neurological ailments. While the journal is not open access, its valuable content—covering the full spectrum of neurological disorders, their epidemiology, and related health implications—remains accessible via institutional subscriptions. With a consistent publication schedule leading up to 2024, NEUROEPIDEMIOLOGY continues to elevate the standards of research and discussion within these dynamic fields.
Metrics 2024
Metrics History
Rank 2024
Scopus
IF (Web Of Science)
JCI (Web Of Science)
Quartile History
Similar Journals
METABOLIC BRAIN DISEASE
Advancing insights into cerebral metabolism.METABOLIC BRAIN DISEASE, published by SPRINGER/PLENUM PUBLISHERS, is a leading journal dedicated to advancing our understanding of the metabolic processes impacting brain health and disease. Established in 1986 and set to continue until 2024, this journal encompasses a wide range of interdisciplinary research that intersects the fields of Biochemistry, Cellular and Molecular Neuroscience, and Neurology, as evidenced by its notable quartile placements in Q2 and Q3 for 2023. With an ISSN of 0885-7490 and an E-ISSN of 1573-7365, it serves as a vital resource for researchers and practitioners aiming to deepen their insights into cerebral metabolic disorders and their implications. Although currently not an Open Access option, its rigorous peer-review process ensures that high-quality, impactful research reaches its audience. Showcasing a significant rank within the top percentile of its categories, METABOLIC BRAIN DISEASE is instrumental in shaping the future of neurological research and clinical applications.
NEUROLOGIC CLINICS
Connecting research and clinical excellence in neurology.NEUROLOGIC CLINICS, published by W B SAUNDERS CO-ELSEVIER INC, stands as a leading journal in the field of clinical neurology, boasting an impressive impact factor that reflects its significant contributions to neurological research and clinical practice. With an ISSN of 0733-8619 and E-ISSN of 1557-9875, this journal provides a critical platform for the dissemination of innovative research, case studies, and reviews focusing on various aspects of neurology, from diagnosis to treatment interventions. As part of its commitment to advancing the understanding of neurological disorders, NEUROLOGIC CLINICS is categorized in the Q2 quartile for Neurology (clinical) in 2023, indicating its robust standing within the academic community. It is recognized for its rigorous peer-review process and is indexed in Scopus, ranking #147 out of 400 in its field with a notable 63rd percentile. The journal, which dates back to 1983 and continues to publish vital findings up to 2024, is an invaluable resource for researchers, healthcare professionals, and students dedicated to enhancing their knowledge and clinical skills in neurology. Subscribe now to stay abreast of current advancements and expand your expertise in this dynamic field.
Archives of Neuroscience
Championing academic excellence in neuroscience exploration.Archives of Neuroscience is a multidisciplinary journal dedicated to advancing the field of neuroscience through the publication of original research articles, review papers, and case studies. Published by BRIEFLAND, this journal aims to bridge the gap between neuroscience research and clinical applications, fostering a deeper understanding of brain function, neurological disorders, and potential therapeutic approaches. With an ISSN of 2322-3944 and an E-ISSN of 2322-5769, Archives of Neuroscience serves as an essential platform for researchers, professionals, and students alike, encouraging open access to knowledge and insights that drive innovation in the field. Although coverage was discontinued in Scopus from 2016 to 2017, the journal continues to uphold rigorous standards of academic excellence, making it a valuable resource for the neuroscience community seeking to explore and disseminate new findings. The journal is committed to providing timely access to research tools and findings that are crucial for informed decision-making in both academic and clinical settings.
LANCET NEUROLOGY
Transforming Clinical Practice Through ResearchThe Lancet Neurology is a premier academic journal published by Elsevier Science Inc, specializing in the field of neurology. With a robust impact factor that signifies its authoritative presence, it consistently ranks in the Q1 category for clinical neurology according to the 2023 standards, positioning itself as the leading journal in its domain, ranking #1 out of 400 in Scopus' neurology rankings and placing in the 99th percentile. Since its establishment in 2002, it has provided a vital platform for disseminating innovative research and clinical advances related to neurological disorders. The journal’s precise focus includes cutting-edge studies on neurodegenerative diseases, stroke, epilepsy, and neuroimaging, which are essential for advancing clinical practice and improving patient outcomes. While it does not offer open access, readers can find high-impact research published monthly, making it indispensable for practitioners, researchers, and students eager to stay at the forefront of neurological science.
EUROPEAN JOURNAL OF NEUROLOGY
Transforming Neurology Through Rigorous Research.EUROPEAN JOURNAL OF NEUROLOGY, published by WILEY, stands as a leading platform for the dissemination of innovative research and clinical developments in the field of neurology. With a robust impact factor and prestigious rankings, including being positioned as Q1 in both Neurology and Clinical Neurology categories, the journal plays a pivotal role in shaping neurological sciences from 1994 to 2024. Its Scopus rank highlights its importance, being in the 88th percentile for clinical neurology and 87th percentile for neuroscience. Located in the United Kingdom, the journal thrives as a vital resource for researchers, clinicians, and students dedicated to improving neurological health outcomes. Although it does not offer Open Access, its subscription-based model ensures high-quality peer-reviewed articles are accessible to a global audience, reflecting the continuous pursuit of excellence in neurological research and patient care.
International Journal of Noncommunicable Diseases
Connecting experts to enhance understanding of NCDs.The International Journal of Noncommunicable Diseases, published by Wolters Kluwer Medknow Publications, is a leading open-access journal dedicated to advancing research in the field of noncommunicable diseases (NCDs). Since its inception in 2016, the journal has provided a robust platform for the dissemination of high-quality studies, reviews, and case reports that address the growing burden of NCDs globally. With a commitment to enhancing knowledge and understanding, the journal aims to navigate the complexities of prevention, diagnosis, management, and policy implications related to diseases such as diabetes, cardiovascular conditions, and cancers. The journal features an inclusive editorial board made up of renowned experts in the field, ensuring rigorous peer review and maintaining a high standard of scholarly excellence. As an open-access journal, it promotes widespread availability of its content, fostering collaboration and innovation among researchers, healthcare professionals, and students alike. Engage with the latest research and contribute to the growing body of knowledge in this critical area of public health by exploring the International Journal of Noncommunicable Diseases.
Expert Review of Vaccines
Exploring Breakthroughs in Vaccine Research and Policy.Expert Review of Vaccines, published by Taylor & Francis Ltd, is a pivotal open access journal that has established itself as a leading source of peer-reviewed articles focusing on vaccine research, development, and policy. With an impressive categorization in the top quartile (Q1) across various domains including Drug Discovery, Immunology, Molecular Medicine, and Pharmacology for 2023, this journal plays a crucial role in disseminating high-quality scientific findings that drive advances in the field. Located in the United Kingdom, it serves a global audience of researchers, healthcare professionals, and students seeking to stay abreast of cutting-edge developments in vaccination strategies and technologies. The journal’s Scopus ranks further attest to its excellence, boasting remarkable placements in Pharmacology and Drug Discovery, reflecting its impact and reach. Since transitioning to an open access format in 2023, the journal has enhanced accessibility to vital research, empowering a broader audience to contribute to and engage with the discourse surrounding vaccines. As the field of immunization continues to evolve, Expert Review of Vaccines remains a cornerstone for those committed to advancing knowledge and practice in this essential area of health science.
Therapeutic Advances in Neurological Disorders
Advancing knowledge for a brighter neurological future.Therapeutic Advances in Neurological Disorders, published by SAGE Publications Ltd, is a leading open access journal dedicated to the advancement of knowledge in the field of neurology. Since its inception in 2008, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for the dissemination of high-quality research that improves the understanding and treatment of neurological disorders. With a commendable impact factor and ranked Q1 in multiple categories, including Neurology and Pharmacology for 2023, it exemplifies excellence in scholarly contributions. The journal's Scope encompasses a wide array of topics, providing insights that are pivotal for clinical practice and pharmacological development. Additionally, with its commitment to open access since 2017, Therapeutic Advances in Neurological Disorders ensures that its research reaches a global audience, fostering collaboration and innovation in neurological science.
NEUROLOGY
Fostering excellence in the study of neurological disorders.NEUROLOGY, published by Lippincott Williams & Wilkins, stands as a premier journal in the field of neurology, holding an esteemed Q1 category ranking in clinical neurology as of 2023. Established in 1951, this journal has been a critical resource for the dissemination of cutting-edge research and clinical advancements, with an impressive Scopus rank of 24 out of 400, placing it in the 94th percentile among its peers. NEUROLOGY serves as a vital platform for neurologists, researchers, and medical professionals seeking to stay abreast of the latest findings and innovations in the treatment and understanding of neurological disorders. With its rigorous peer-review process and commitment to excellence, NEUROLOGY remains essential reading for all individuals dedicated to advancing the science and practice of neurology, contributing significantly to the ongoing dialogue in this vital area of medicine.
DM DISEASE-A-MONTH
Connecting You to the Pulse of Medical Innovation.DM DISEASE-A-MONTH is a leading monthly journal published by MOSBY-ELSEVIER, dedicated to disseminating pivotal research and insights across the spectrum of general medicine. With a history spanning from 1954 to 2024, this journal has established itself as a key resource within the field, reflecting its commitment to advancing medical knowledge and practice. As evidenced by its impressive Scopus ranking—currently at #79 out of 636 in General Medicine and falling within the 87th percentile—this journal occupies a prominent position in the medical literature landscape. Although not an open-access publication, DM DISEASE-A-MONTH continues to serve a diverse audience of researchers, healthcare professionals, and medical students, providing valuable updates on recent advances in medicine and enabling its readers to stay informed about emerging trends and critical health issues. Its current Q2 category ranking in the 2023 Medical (miscellaneous) field further underscores its relevance and impact, making it an essential addition to the library of any medical practitioner or researcher.